We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Telesis Bio Inc (TBIO) USD0.0001

Sell:$3.45 Buy:$3.56 Change: $0.18 (4.96%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.18 (4.96%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
Change: $0.18 (4.96%)
Market closed |  Prices as at close on 21 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

Contact details

10431 Wateridge Circle, Suite 150
United States
+1 (858) 2284115

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$6.34 million
Shares in issue:
1.67 million
Life Sciences Tools & Services
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Eric Esser
    President, Chief Executive Officer, Director
  • William Kullback
    Chief Financial Officer
  • Daniel Gibson
    Chief Technology Officer
  • Robert Cutler
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.